Teva Pharmaceuticals

A global pharmaceutical company specializing in the development, production, and marketing of generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients.

Health Tech & Life Sciences
public
Public Tel Aviv, Israel Founded 1901
Last updated 2026-11-03
Total raised
$76.7B
Last: Debt Financing 2026-03
Stage
Public
Founded
1901
Headcount
36,830
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences

About

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company specializing primarily in generic drugs, but also in branded-drugs, active pharmaceutical ingredients (APIs), and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva focuses on innovative medicine for various therapeutic areas including neuroscience and immunology for non- and rare diseases. The company's portfolio covers a wide range of therapeutic areas, including central nervous system disorders, respiratory conditions, oncology, and more. Teva aims to help patients live longer, healthier lives and is dedicated to addressing patients' needs, now and in the future.

Funding history · 31 rounds · $76.7B total

31 events/rounds · $76.7B Total Funding: $8.2B in Private Equity, $14.3B in Public Equity, $53.3B in Debt
Sep 2026
Debt Financing $1.6B stocktitan.net ↗
★ Teva Finance II★ Teva Finance IV★ Teva Finance III
Sep 2026
Debt Financing $4.9B globenewswire.com ↗
★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands IV B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Apr 2026
Grant $900.0M prior (startupim db)
★ Direct Relief★ National Association of Free and Charitable Clinics (NAFC)
Mar 2026
Public Offering $400.0M prior (startupim db)
Jan 2026
Debt Financing $500.0M tevapharm.com ↗
★ Royalty PharmaPublicJKI Co., Ltd.Public investorsTeva Pharmaceutical Finance Netherlands III B.V.
Jan 2026
Public Offering $2.3B prior (startupim db)
Nov 2025
Grant Undisclosed ynetnews.com ↗
★ Startup Nation Central★ Israel Innovation Authority
May 2025
Debt Financing $2.0B tevapharm.com ↗
★ HSBC★ Public★ BNP PARIBAS★ J.P. Morgan★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands IV B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.MUFGMizuhoCitigroupHSBC Bank plcBofA SecuritiesIMI-Intesa SanpaoloIntesa Sanpaolo S.p.A.PNC Capital Markets LLCJ.P. Morgan Securities plcMerrill Lynch InternationalGoldman Sachs Bank Europe SE
Mar 2024
PIPE $150.0M prior (startupim db)
Jan 2024
Public Offering $10.0B prior (startupim db)
★ Public
Nov 2023
Debt Financing $100.0M sec.gov ↗
★ Royalty Pharma
Mar 2023
Debt Financing $864.0M prior (startupim db)
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Mar 2023
Debt Financing $500.0M prior (startupim db)
Nov 2021
Debt Financing $1.0B prior (startupim db)
Nov 2021
Public Offering $1.6B prior (startupim db)
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Jan 2018
PIPE $1.3B prior (startupim db)
★ Public★ JANA Partners★ Public investors★ Fidelity Ventures★ Berkshire Hathaway★ Fidelity Investments★ Teva Pharmaceutical Finance Netherlands III B.V.
Jul 2016
Debt Financing $3.5B prior (startupim db)
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands III B.V.
Jul 2016
Debt Financing $2.0B prior (startupim db)
Jul 2015
Debt Financing $33.8B tevapharm.com ↗
★ Citi★ BNP Paribas★ Mizuho Bank★ Credit Suisse★ Barclays Bank PLC★ Bank of America Merrill Lynch★ HSBC Ventures★ Morgan Stanley Senior Funding, Inc.HSBCRBC Capital MarketsMorgan Stanley Senior FundingSumitomo Mitsui Banking Corporation
Apr 2012
Debt Financing $1.1B prior (startupim db)
Mar 2012
Public Offering Undisclosed nocamels.com ↗
May 2011
D Round $6.8B prior (startupim db)
Sep 2007
C Round Undisclosed globes.co.il ↗
★ Teva★ Teva PharmaceuticalsTeva Pharmaceutical Industries
Feb 2006
Debt Financing $1.0B prior (startupim db)
Feb 2006
Debt Financing $500.0M prior (startupim db)
Feb 2005
A Round Undisclosed prior (startupim db)
Feb 1987
Public Offering Undisclosed prior (startupim db)
★ NASDAQPublic
1982
Public Offering Undisclosed prior (startupim db)
Dec 1981
Public Offering Undisclosed prior (startupim db)
Jan 1951
Public Offering Undisclosed prior (startupim db)
★ Tel Aviv Stock Exchange (TASE)★ Public (Tel-Aviv Stock Exchange)Public
May 1935
Seed Undisclosed prior (startupim db)
★ Else Kober★ Günther Friedländer★ loans from German immigrants★ Günther Friedländer family capitalFamily capitalAlfred FeuchtwangerFamily's own capitalloans from other German immigrants

Acquisitions · 27

Oct 2026
BioXcel Therapeutics (neuroscience assets) $57.5M
Jun 2026
Emalex Biosciences $700.0M
Oct 2016
Anda $500.0M
Aug 2016
Actavis Generics $40.0B
Oct 2015
Rimsa $2.3B
Oct 2015
Gecko Health Innovations Undisclosed
Mar 2015
Auspex Pharmaceuticals $3.5B
Jun 2014
Labrys Biologics $825.0M
Jan 2014
NuPathe $144.0M
Jun 2013
MicroDose Therapeutx $165.0M
Jul 2011
Taiyo Pharmaceutical Industry $934.0M
May 2011
Cephalon $6.8B
Mar 2010
Ratiopharm $5.0B
Dec 2008
Barr Pharmaceuticals $7.5B
Jul 2008
Bentley Pharmaceuticals (generic operations) $360.0M
Jan 2006
Ivax Corporation $7.4B
Jan 2004
Sicor, Inc. Undisclosed
Jan 2000
Novopharm Undisclosed
Aug 1999
Copley Pharmaceutical $220.0M
Jan 1996
Biocraft Undisclosed
Jan 1995
Biogal Gyógyszergyár Rt. Undisclosed
Jan 1995
ICI (Italy) Undisclosed
Jan 1985
Lemmon Pharmacal Company Undisclosed
Jan 1980
Ikapharm Undisclosed
Jan 1980
Plantex Undisclosed
Jan 1976
Assia and Zori Undisclosed
Date unknown
Orphahell Undisclosed

Offices

Tel Aviv, Israel · HQ / main office

Q&A

What is Teva Pharmaceuticals' primary focus?
Teva Pharmaceuticals is an Israeli multinational pharmaceutical company specializing primarily in generic drugs, but also in branded-drugs, active pharmaceutical ingredients (APIs), and contract manufacturing services.
When was Teva Pharmaceuticals founded and where is its headquarters?
Teva Pharmaceuticals was founded in 1901 and is headquartered in Tel Aviv, Israel.
How many employees does Teva Pharmaceuticals have?
Teva Pharmaceuticals has over 500 employees.
What was Teva Pharmaceuticals' most recent debt financing round?
In September 2026, Teva Pharmaceuticals secured a Debt Financing round worth $4.9 billion from Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands IV B.V., and Teva Pharmaceutical Finance Netherlands III B.V.
What was Teva Pharmaceuticals' most recent Public Offering?
In March 2026, Teva Pharmaceuticals had a Public Offering of $400 million, with investors including Blackstone.
What was Teva Pharmaceuticals' most recent acquisition?
In October 2026, Teva Pharmaceuticals acquired the neuroscience assets of BioXcel Therapeutics for $57.5 million.
Which company did Teva Pharmaceuticals acquire in June 2026?
In June 2026, Teva Pharmaceuticals acquired Emalex Biosciences for $700 million.
What was the amount of the PIPE round Teva Pharmaceuticals received in March 2024?
In March 2024, Teva Pharmaceuticals received a PIPE round of $150 million from Abingworth.

Team · 23

Chaim Salomon
Founder · founders
Moshe Levin
Founder · founders
Yitschak Elstein
Founder · founders
Günther Friedländer
Founder · founders
Richard Francis
President and CEO
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
Dr. Eric A. Hughes
Executive Vice President, Global R&D and Chief Medical Officer
Richard Daniell
Executive Vice President, European Commercial
Christine Fox
Executive Vice President, US Commercial, Head of Innovative Franchise
Placid Jover
Executive Vice President, Chief Human Resources Officer
Evan Lippman
Executive Vice President, Business Development
Mark Sabag
Executive Vice President, International Markets Commercial
Matthew Shields
Executive Vice President, Teva Global Operations
Nir Baron
Senior Vice President, Chief Internal Auditor
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer
Sol Barer
Chairman
Rosemary A. Crane
board
Amir Elstein
board
Chen Lichtenstein
board
Gerald M. Lieberman
board
Roberto A. Mignone
board
Dr. Perry D. Nisen
board
Prof. Ronit Satchi-Fainaro
board

Sectors & technology

Primary sector
Health Tech & Life Sciences
Target customers
Business model
B2BB2C

Highlights

Patents

Tags

respiratorywomen-healthneurologyoncologygeneric-drugsbiological-therapypharmaceuticalspatientsbiopharmaceuticalnanotechnologychronic-patientsdrug-deliverydoctorsmedical-cannabis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitetevapharm.com
LinkedInlinkedin.com/company/5239
X / Twittertwitter.com/tevapharm
Facebookfacebook.com/tevapharm
YouTubeyoutube.com/channel/UC9mY1-jUvXsEIS5A2_EjpFg
Wikipediaen.wikipedia.org/wiki/Teva_Pharmaceuticals
Wikidatawikidata.org/wiki/Q898750

Identifiers & details

Legal nameTeva Pharmaceutical Industries Ltd.
Founded1901
Employees (exact)36830
Wikidata QIDQ898750

Acquisitions & public offerings

AcquiredDateAmount
BioXcel Therapeutics (neuroscience assets)2026-10$57.5M
Emalex Biosciences2026-06$700.0M
Anda2016-10$500.0M
Actavis Generics2016-08$40.0B
Rimsa2015-10$2.3B
Gecko Health Innovations2015-10
Auspex Pharmaceuticals2015-03$3.5B
Labrys Biologics2014-06$825.0M
NuPathe2014-01$144.0M
MicroDose Therapeutx2013-06$165.0M
Taiyo Pharmaceutical Industry2011-07$934.0M
Cephalon2011-05$6.8B
Ratiopharm2010-03$5.0B
Barr Pharmaceuticals2008-12$7.5B
Bentley Pharmaceuticals (generic operations)2008-07$360.0M
Ivax Corporation2006-01$7.4B
Sicor, Inc.2004-01
Novopharm2000-01
Copley Pharmaceutical1999-08$220.0M
Biocraft1996-01
Biogal Gyógyszergyár Rt.1995-01
ICI (Italy)1995-01
Lemmon Pharmacal Company1985-01
Ikapharm1980-01
Plantex1980-01
Assia and Zori1976-01
Orphahell

Radar intelligence

Patents

EPO1106

App Store

AppRatingRatings
Teva Pharmaceutical Events
Teva Meetings

Web history (Wayback)

Domaintevapharm.com

Wikidata

QIDQ898750

Certificate / subdomain footprint

Subdomains200